ROLE OF ROSUVASTATIN PRETREATMENT IN PREVENTION OF CONTRAST INDUCED NEPHROPATHY IN PATIENTS UNDERGOING CORONARY ANGIOGRAPHY

Abstract

Objective: The aim of this study was to assess the efficacy of short-term highdose
rosuvastatin pretreatment therapy for the prevention of contrast induced
nephropathy.
Methodology: This study prospectively included two hundred patients who
underwent coronary angiography, and were randomized into two groups: control
group (included 100 patients who did not receive statin therapy) and statin group
(included 100 patients who received rosuvastatin 20 mg/day 3 days before and 7
days after coronary angiography).According to recommendations of the National
kidney foundation, results had been recorded using both serum creatinine and
glomular filteration rate levels.
Results: There was statistically significant reduction in the occurrence of
contrast-induced nephropathy in rosuvastatin pretreated patients ("22%" and
"15%" of them developed contrast-induced nephropathy regarding the glomular
filteration rate and serum creatinine levels respectively), compared to those in the
control group ("35%" and "38%" regarding the glomular filteration rate and serum
creatinine levels respectively) with P-value (<0.001 regarding serum creatinine
and <0.042 regarding glomular filteration rate).
Conclusion: This study favors statin pretreatment for preventing contrast
induced nephropathy in patients undergoing coronary angiography.